BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,”
3 of 3
Receive JSR Life Sciences news on your RSS reader.
